Weiss, Matthew M. et al. published their research in Journal of Medicinal Chemistry in 2017 | CAS: 5469-70-5

3-Aminopyridazine (cas: 5469-70-5) belongs to pyridazine derivatives. The pyridazine derivatives are mostly present in biologically active compounds and are also present with different pharmacophores. Pyridazine is bioavailable (especially in the CNS) and can reduce toxicity. Pyridazine is a component of several drug molecules, and the pyridazine pharmacophore has contributed to a variety of pharmacologically active compounds.Recommanded Product: 3-Aminopyridazine

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities was written by Weiss, Matthew M.;Dineen, Thomas A.;Marx, Isaac E.;Altmann, Steven;Boezio, Alessandro;Bregman, Howard;Chu-Moyer, Margaret;DiMauro, Erin F.;Feric Bojic, Elma;Foti, Robert S.;Gao, Hua;Graceffa, Russell;Gunaydin, Hakan;Guzman-Perez, Angel;Huang, Hongbing;Huang, Liyue;Jarosh, Michael;Kornecook, Thomas;Kreiman, Charles R.;Ligutti, Joseph;La, Daniel S.;Lin, Min-Hwa Jasmine;Liu, Dong;Moyer, Bryan D.;Nguyen, Hanh N.;Peterson, Emily A.;Rose, Paul E.;Taborn, Kristin;Youngblood, Beth D.;Yu, Violeta;Fremeau, Robert T.. And the article was included in Journal of Medicinal Chemistry in 2017.Recommanded Product: 3-Aminopyridazine This article mentions the following:

Several reports have recently emerged regarding the identification of heteroarylsulfonamides as NaV1.7 inhibitors that demonstrate high levels of selectivity over other NaV isoforms. The optimization of a series of internal NaV1.7 leads that address a number of metabolic liabilities including bioactivation, PXR activation, as well as CYP3A4 induction and inhibition led to the identification of potent and selective inhibitors that demonstrated favorable pharmacokinetic profiles and were devoid of the aforementioned liabilities. The key to achieving this within a series prone to transporter-mediated clearance was the identification of a small range of optimal cLogD values and the discovery of subtle PXR SAR that was not lipophilicity dependent. This enabled the identification of compound 20, which was advanced into a target engagement pharmacodynamic model where it exhibited robust reversal of histamine-induced scratching bouts in mice. In the experiment, the researchers used many compounds, for example, 3-Aminopyridazine (cas: 5469-70-5Recommanded Product: 3-Aminopyridazine).

3-Aminopyridazine (cas: 5469-70-5) belongs to pyridazine derivatives. The pyridazine derivatives are mostly present in biologically active compounds and are also present with different pharmacophores. Pyridazine is bioavailable (especially in the CNS) and can reduce toxicity. Pyridazine is a component of several drug molecules, and the pyridazine pharmacophore has contributed to a variety of pharmacologically active compounds.Recommanded Product: 3-Aminopyridazine

Referemce:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem